TY - JOUR
T1 - Lipid-lowering therapy for the primary prevention of coronary heart disease
AU - Gotto, Antonio M.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 1999/6
Y1 - 1999/6
N2 - Primary prevention of coronary heart disease is a critical component of reducing the societal burden of atherosclerosis. In the current editorial, data from trials of lipid modification as primary-prevention strategies will be reviewed. Trials of the HMG-CoA reductase inhibitors have demonstrated significant benefits on coronary morbidity in patients without heart disease, and the implications of these studies on current guidelines will be discussed with a focus on the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
AB - Primary prevention of coronary heart disease is a critical component of reducing the societal burden of atherosclerosis. In the current editorial, data from trials of lipid modification as primary-prevention strategies will be reviewed. Trials of the HMG-CoA reductase inhibitors have demonstrated significant benefits on coronary morbidity in patients without heart disease, and the implications of these studies on current guidelines will be discussed with a focus on the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
UR - http://www.scopus.com/inward/record.url?scp=0344614497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0344614497&partnerID=8YFLogxK
U2 - 10.1016/S0735-1097(99)00114-X
DO - 10.1016/S0735-1097(99)00114-X
M3 - Article
C2 - 10362217
AN - SCOPUS:0344614497
SN - 0735-1097
VL - 33
SP - 2078
EP - 2082
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 7
ER -